The pharmaceutical industry is currently undergoing an unprecedented transformation as digital technologies permeate all aspects of the classical pharmaceutical value stream – and the COVID crisis has only highlighted the importance of going digital!
Find out more in our whitepaper.
Digital solutions across 6 steps of the value chain
Discovery, Development, Manufacturing, Supply Chain, Commercial, Healthcare. Avertim has gathered in the whitepaper for you key insights and use cases to inspire you and help you reach digital success within these 6 areas of the value chain!
Various digital technologies are available today
As a highly innovative science based sector, pharmaceuticals can benefit greatly from the integration of common digital tools as well as novel technologies like big data, advanced analytics, process mining, cloud computing, smart devices, artificial intelligence (AI) and blockchain technologies.
Companies are leveraging these technologies to create effective solutions aiming to:
- Optimize general business process workflow with process automation, process mining, digital platforms and analytics solutions
- Reshape data storing, sharing, monetization in discovery and development, but also in clinical trials or patient data management
- Switch to digital platforms for Quality Management (eQMS), data tracking, Document Management Systems (eDMS), Manufacturing Execution Systems (MES) including electronic Batch Records Management (eBR) or other paperless solutions such as Laboratory Execution Systems (LES)
- Pilot emerging technologies such as blockchain or AI solutions to help in areas such as preventive maintenance, anti-counterfeiting; but also to generate new business models among others in healthcare and patient-focused services
Benefits identified: speed and cost, but not only
With improved data sharing, collaboration, automation and management along the whole pharmaceutical life cycle, these technologies can offer new ways to discover, develop, manufacture, and deliver drugs and patient treatments.
Reduced time-to-market and costs, enhanced traceability, creation of new data-driven healthcare business models and new relationships with patients are some of the key benefits companies are seeking when implementing digital transformation programs.
Impact of COVID in the digital transformation
The SARS-CoV-2 induced COVID-19 pandemic has made it clear that traditional analogue ways of working in the pharmaceutical industry are inadequate to overcome such global health crises within socially and economically acceptable time frames. Long vaccine and drug development timelines – sometimes more than fifteen years from initial research to market entry – must be reduced by all means.
Some of the cases used in the whitepaper
The following organizations are mentioned or quoted in the whitepaper:
